Pulmonary Nocardiosisin an ImmunocompetentHost by Grant, Leah et al.
Providence St. Joseph Health 
Providence St. Joseph Health Digital Commons 
Providence St. Vincent Internal Medicine Oregon Academic Achievement 
4-29-2020 
Pulmonary Nocardiosisin an ImmunocompetentHost 
Leah Grant 
Providence St. Vincent, Internal Medicine Residency, Portland, Oregon 
Laura Loertscher 
Providence St. Vincent, Portland, Oregon, LAURA.LOERTSCHER@providence.org 
Jennifer Marfori 
Providence St. Vincent, Portland, Oregon, Jennifer.Marfori@providence.org 
Follow this and additional works at: https://digitalcommons.psjhealth.org/psv_internal 
 Part of the Internal Medicine Commons 
Recommended Citation 
Grant, Leah; Loertscher, Laura; and Marfori, Jennifer, "Pulmonary Nocardiosisin an 
ImmunocompetentHost" (2020). Providence St. Vincent Internal Medicine. 7. 
https://digitalcommons.psjhealth.org/psv_internal/7 
This Poster is brought to you for free and open access by the Oregon Academic Achievement at Providence St. 
Joseph Health Digital Commons. It has been accepted for inclusion in Providence St. Vincent Internal Medicine by 
an authorized administrator of Providence St. Joseph Health Digital Commons. For more information, please 
contact digitalcommons@providence.org. 
Pulmonary Nocardiosis in an Immunocompetent Host
Leah Grant MD, Laura Loertscher MD, Jennifer Marfori MD
Introduction
• Nocardia is known to cause severe pulmonary or 
disseminated infection in immunocompromised patients, 
but can cause infection in immunocompetent patients. 
Providers should consider Nocardiosis in immunocompetent 
patients with prolonged and unexplained respiratory failure.
• The preferred therapy for pulmonary Nocardiosis is a sulfa 
antibiotic for 3-6 months. Toxicity from prolonged use of 
alternative agents presents a therapeutic challenge in those 
with sulfa allergy.
Case Report
• An 85 year-old woman with a history of paroxysmal atrial 
fibrillation and heart failure with preserved EF presented to 
her primary care provider with 1 week of cough and 
progressive dyspnea. Chest x-ray (CXR) was normal, and 
echocardiogram demonstrated known HFpEF without new 
abnormalities.
• Two months later, she presented to the hospital with 
progressive dyspnea, chest tightness, and was found to be 
hypoxic. CXR on admission showed bilateral consolidations as 
well as mediastinal and hilar adenopathy. She was treated 
with ceftriaxone & azithromycin for presumed community-
acquired pneumonia (CAP).
• Due to treatment failure, a CT Chest was obtained and 
showed a mass-like consolidation in the right middle lobe; 
she was discharged with a several-week prednisone taper for 
treatment of presumed cryptogenic organizing pneumonia.
• Two weeks later, she returned for worsening dyspnea, chest 
pressure, malaise, and hypoxia. She was again treated for 
CAP and discharged.
• One month later, she was admitted for similar symptoms, and 
a CT-guided lung biopsy showed several small clusters of long 
Gram-positive bacteria consistent with Nocardia spp. Tissue 
culture was positive for Nocardia cyriacigeorgica complex.
• The patient was offered a challenge of her sulfa allergy 
(reported as a rash), but refused. She was started on linezolid 
in anticipation of a 6 month course of therapy.
• Her hospitalization was complicated by cardiac & renal 
dysfunction. Due to severely impaired quality of life, the 
patient elected for hospice care and died approximately 2 
weeks after discharge.
Discussion
Figures: Chest x-ray on admission with bilateral consolidations (top). CT Chest on second admission with RML consolidation (right). Pathology slide showing 
Gram-positive branching rods consistent with Nocardia (bottom left). 
• Nocardiosis most commonly presents as a pulmonary infection as inhalation is the primary route of 
exposure.
• More than half of all reported Nocardiosis cases are associated with preexisting immunocompromise 
such as organ transplantation, AIDS, diabetes, chronic granulomatous disease and alcoholism. More 
recently published case reports depict Nocardia infections in immunocompetent patients with a prior 
history of lung disease, such as chronic obstructive pulmonary disease, allergic bronchopulmonary 
aspergillosis, and bronchiectasis.
• Our patient was neither immunocompromised, nor had a prior history of lung disease, though was an 
elderly person. Immunosenescence is associated with decline in innate as well as T-cell immunity, 
which may have imparted risk to our patient.
• The mainstay for treatment of Nocardia infections is trimethoprim-sulfamethoxazole (TMP-SMX). 
Alternative oral agents include minocycline, amoxicillin-clavulanate, and linezolid.
• Had our patient not chosen the route of hospice care, close monitoring for linezolid toxicity would have 
been necessary with possible TMP-SMX re-challenge for long term therapy.
